Early detection of chronic kidney disease in low-income and middle-income countries: development and validation of a point-of-care screening strategy for India.

community-based survey epidemiology screening

Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
2019
Historique:
received: 18 04 2019
revised: 12 07 2019
accepted: 29 07 2019
entrez: 24 9 2019
pubmed: 24 9 2019
medline: 24 9 2019
Statut: epublish

Résumé

Although deaths due to chronic kidney disease (CKD) have doubled over the past two decades, few data exist to inform screening strategies for early detection of CKD in low-income and middle-income countries. Using data from three population-based surveys in India, we developed a prediction model to identify a target population that could benefit from further CKD testing, after an initial screening implemented during home health visits. Using data from one urban survey (n=8698), we applied stepwise logistic regression to test three models: one comprised of demographics, self-reported medical history, anthropometry and point-of-care (urine dipstick or capillary glucose) tests; one with demographics and self-reported medical history and one with anthropometry and point-of-care tests. The 'gold-standard' definition of CKD was an estimated glomerular filtration rate <60 mL/min/1.73 m A model with age, sex, waist circumference, body mass index and urine dipstick had a c-statistic of 0.76 (95% CI 0.75 to 0.78) for predicting need for further CKD testing, with external validation c-statistics of 0.74 and 0.70 in the urban and rural cohorts, respectively. At a probability cut-point of 0.09, sensitivity was 71% (95% CI 68% to 74%) and specificity was 70% (95% CI 69% to 71%). The model captured 71% of persons with CKD and 90% of persons at highest risk of complications from untreated CKD (ie, CKD stage 3A2 and above). A point-of-care CKD screening strategy using three simple measures can accurately identify high-risk persons who require confirmatory kidney function testing.

Identifiants

pubmed: 31544000
doi: 10.1136/bmjgh-2019-001644
pii: bmjgh-2019-001644
pmc: PMC6730594
pii:
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e001644

Subventions

Organisme : NIDDK NIH HHS
ID : K24 DK085446
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007357
Pays : United States

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Can J Kidney Health Dis. 2017 Aug 09;4:2054358117722782
pubmed: 28835850
Am J Med. 2010 Sep;123(9):836-846.e2
pubmed: 20800153
Rev Panam Salud Publica. 2004 Nov;16(5):320-7
pubmed: 15729981
PLoS Med. 2015 May 19;12(5):e1001827; discussion e1001827
pubmed: 25992895
Ann Intern Med. 2012 Oct 16;157(8):567-70
pubmed: 22928170
PLoS One. 2012;7(8):e43400
pubmed: 22916256
Am J Kidney Dis. 2009 Mar;53(3 Suppl 3):S64-70
pubmed: 19231763
Kidney Int. 2007 Aug;72(3):247-59
pubmed: 17568785
Kidney Int. 2018 Sep;94(3):567-581
pubmed: 30078514
Adv Chronic Kidney Dis. 2011 Jul;18(4):258-66
pubmed: 21782132
BMC Nephrol. 2011 Sep 26;12:45
pubmed: 21943205
BMC Public Health. 2012 Aug 28;12:701
pubmed: 22928740
Lancet. 2013 Jul 20;382(9888):260-72
pubmed: 23727169
PLoS Med. 2012;9(11):e1001344
pubmed: 23185136
Nephrology (Carlton). 2012 Mar;17(3):278-84
pubmed: 22171932
BMJ. 2010 Nov 08;341:c5869
pubmed: 21059726
Lancet. 2015 May 16;385(9981):1975-82
pubmed: 25777665
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
BMJ Open. 2018 Jul 10;8(6):e015919
pubmed: 29991625
Lancet. 2018 Mar 24;391(10126):1224-1236
pubmed: 29108723
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
JAMA. 2015 Aug 11;314(6):615-6
pubmed: 26262800
BMC Nephrol. 2015 Jul 04;16:94
pubmed: 26140920
Eur J Cardiovasc Prev Rehabil. 2007 Feb;14(1):107-13
pubmed: 17301635
Am J Kidney Dis. 2014 May;63(5):789-97
pubmed: 24529536
Am J Kidney Dis. 2008 Oct;52(4):778-87
pubmed: 18676076
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
BMJ Glob Health. 2017 Oct 9;2(4):e000453
pubmed: 29071132
Am J Kidney Dis. 2014 Jan;63(1):49-58
pubmed: 24074822

Auteurs

Christina Bradshaw (C)

Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA cbradsha@stanford.edu.

Dimple Kondal (D)

Public Health Foundation of India, New Delhi, Delhi, India.
Centre for Chronic Disease Control, Gurgaon, Haryana, India.

Maria E Montez-Rath (ME)

Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.

Jialin Han (J)

Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.

Yuanchao Zheng (Y)

Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.

Roopa Shivashankar (R)

Centre for Chronic Disease Control, Gurgaon, Haryana, India.

Ruby Gupta (R)

Public Health Foundation of India, New Delhi, Delhi, India.

Nikhil Srinivasapura Venkateshmurthy (N)

Public Health Foundation of India, New Delhi, Delhi, India.

Prashant Jarhyan (P)

Public Health Foundation of India, New Delhi, Delhi, India.

Sailesh Mohan (S)

Public Health Foundation of India, New Delhi, Delhi, India.

Viswanathan Mohan (V)

Department of Diabetology, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India.

Mohammed K Ali (MK)

Department of Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.

Shivani Patel (S)

Department of Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.

K M Venkat Narayan (KMV)

Department of Global Health, Emory University School of Public Health, Atlanta, Georgia, USA.

Nikhil Tandon (N)

Department of Endocrinology and Metabolism, All India Institute of Medical Sciences, New Delhi, Delhi, India.

Dorairaj Prabhakaran (D)

Public Health Foundation of India, New Delhi, Delhi, India.
Centre for Chronic Disease Control, Gurgaon, Haryana, India.

Shuchi Anand (S)

Division of Nephrology, Stanford University School of Medicine, Stanford, California, USA.

Classifications MeSH